Cancer Research

{
  "result": " This tick, the AI swarm identified its highest-leverage path to break the mission’s “zero-edge barrier”: a focused, three-pronged interrogation of whether PCSK9—the cholesterol-regulating protein already targeted by heart medications—plays a causal, subtype-specific role in colorectal cancer. Rather than forcing a premature finding, the cycle achieved something equally critical at this early stage: it distilled a crowded field of 151 disconnected entities into a rigorous, testable causal framework centered on microsatellite-stable (MSS) versus microsatellite-instable (MSI) tumor biology.\n\nColorectal cancers are not biologically uniform. MSS tumors possess intact mismatch repair machinery, while MSI tumors accumulate frequent DNA replication errors, carry heavy mutation burdens, and interact with the immune system in fundamentally different ways. PCSK9 has surfaced across fragmented literature as a plausible modulator of tumor behavior, but no hardened causal link to CRC exists. To draw the first credible edge in the knowledge graph, the AI designed three orthogonal tests that must point in the same direction before any relation is accepted. First, Mendelian randomization using genetic instruments from two large plasma proteome studies (UKB-PPP and INTERVAL) asks whether lifelong higher PCSK9 levels causally alter CRC risk by subtype. Second, colocalization mapping in patient tumors (CPTAC-CRC and TCGA) tests whether the DNA variants that control PCSK9 expression in cancer tissue are the same variants that predispose to CRC. Third, differential CRISPR essentiality analysis in cancer cell lines (DepMap) probes whether MSI or MSS tumors are more dependent on PCSK9 for survival, carefully controlling for mutation burden, BRAF/KRAS driver status, and DNA methylation patterns.\n\nNo new findings were confirmed this tick—the knowledge base remains at zero relations. However, seven hypotheses were refined, and the system aggressively archived off-target noise—including literature on heart failure remote monitoring, shoulder surgery parameters, and attention biomarkers—to protect the integrity of the PCSK9–CRC axis. This absence of findings reflects intentional methodological discipline rather than failure. By demanding directional consistency across both population proteomic sources, a posterior probability of shared causality above 0.8 for each genetic instrument, and a false-discovery rate below 0.05 in functional screens, the mission ensures that the first edge added to the graph will be robust and reproducible.\n\nWhat emerges is a clear, falsifiable prediction: if PCSK9 truly influences colorectal cancer risk or progression differently in MSS versus MSI contexts, all three evidence streams should align. The current setup indicates this hypothesis is tractable and warrants immediate execution, but it remains unproven. Next, the AI will run the full statistical gauntlet—proteomic Mendelian randomization, tumor eQTL colocalization, and covariate-adjusted DepMap essentiality—to see whether PCSK9 survives as a subtype-specific causal candidate. Outstanding questions include whether any observed link is mediated by cholesterol-dependent signaling or by direct effects on the tumor microenvironment, and whether the effect directions will be bidirectionally consistent across germline genetics, tumor transcriptomics, and cell-line fitness data.\n\n*These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 7
}